^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
Excerpt:
Known deleterious or suspected deleterious germline or somatic BRCA1/2 mutations or with documented HRD
Trial ID:
